The University of Oxford spinout has filed for an $86.25m initial public offering in the US just three years after being founded.
Initial public offerings have been a rare sight in the university venturing world so far this year. In fact, not much has happened since G1 Therapeutics, an oncology therapy developer spun out from North Carolina University, filed for an $115m IPO back in April.
Nightstarx, a spinout from University of Oxford that is working on retinal gene therapies, filing for an initial public offering worth $86.25m in the US yesterday therefore could already be considered a big deal in and…
